Fibrogenesis is the process by which the body builds scar tissue, and it sits at the center of an enormous range of chronic diseases. Whenever tissue is damaged, the body launches a repair program that lays down tough structural proteins, especially collagen, to patch the wound. In a healthy scenario, this program switches off once the job is done. In fibrogenesis gone wrong, the program never fully shuts down, and stiff, collagen-dense scar tissue accumulates in organs where it does not belong. The result can be a stiff liver that no longer filters blood properly, lungs that cannot expand, a heart that pumps inefficiently, or kidneys that lose their ability to filter waste. Understanding how fibrogenesis starts, sustains itself, and might be reversed is one of the most active areas in biomedical research today.
What Kicks the Process Off
Fibrogenesis begins as a normal part of wound healing. After significant tissue injury, such as severe burns, surgery, or trauma, the body moves through overlapping repair phases: inflammation, cell proliferation, and tissue remodeling.1Europe PMC. Current Approaches Targeting the Wound Healing Phases to Attenuate Fibrosis and Scarring During inflammation, immune cells flood the damaged area and clear debris. During proliferation, new cells and blood vessels fill the gap. During remodeling, collagen fibers are reorganized and, ideally, excess matrix is removed. When any of these phases stalls or overshoots, the wound repair machinery keeps producing scar material well past the point of usefulness.
The triggers are not limited to physical trauma. Chronic viral infections like hepatitis, autoimmune conditions, prolonged alcohol use, metabolic disorders like fatty liver disease, and even radiation therapy can all push tissues into a fibrogenic state. Radiation-induced fibrosis, for instance, results from a misguided wound-healing response: ionizing radiation generates reactive oxygen and nitrogen species that cause sustained inflammation, which then evolves into chronic collagen deposition, poor blood supply, and scarring.2PubMed Central. Radiation-induced fibrosis: mechanisms and implications for therapy This can continue affecting patients long after treatment ends, driven by persistent fibroblast activation and accumulation of extracellular matrix material.3PubMed. Exploring radiation-induced fibrosis: biological mechanisms and new frontiers in research and therapeutics
The Central Role of TGF-β
If fibrogenesis has a master switch, it is a signaling molecule called transforming growth factor beta, or TGF-β. This protein is upregulated and activated in fibrotic diseases across virtually every organ. It pushes ordinary fibroblasts to transform into myofibroblasts, the cells that produce the bulk of scar-forming collagen, while simultaneously telling the body to preserve existing matrix rather than break it down.4PubMed Central. TGF-β signaling in fibrosis The net effect is a one-way ratchet: more collagen gets made, less gets removed.
TGF-β does not act on fibroblasts alone. It also activates macrophages, epithelial cells, and the cells lining blood vessels, all of which contribute to the fibrotic environment in their own ways.5PubMed Central. Transforming growth factor-β in tissue fibrosis This broad reach is part of what makes TGF-β so difficult to target therapeutically: blocking it entirely would disrupt immune regulation, wound healing, and cell growth across the whole body. Research has focused on the specific downstream pathways TGF-β activates, hoping to interrupt the fibrotic arm of the signal while leaving the rest intact.
Myofibroblasts and Where They Come From
The workhorse cell of fibrogenesis is the myofibroblast. These are contractile, collagen-secreting cells that do not normally exist in healthy tissue in large numbers. They appear when the body calls for aggressive repair. Most of them arise from local fibroblasts already living in the connective tissue, but when the demand is high enough, the body recruits reinforcements. Local mesenchymal stem cells, bone marrow-derived stem cells, and even epithelial cells that undergo a transformation called epithelial-mesenchymal transition can all become myofibroblasts.6PubMed Central. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair
That last route is particularly important in organs like the lungs, where fibroblastic foci, clusters of active myofibroblasts, appear to wedge themselves between cell layers during idiopathic pulmonary fibrosis. Research has found that these foci push capillary vessels roughly 100 micrometers away from the airway lining, disrupting the tight contact between blood vessels and air-exchanging surfaces that the lung depends on. The cells covering these foci show signs of epithelial-mesenchymal transition, suggesting the foci may partly originate from the lung’s own surface cells rather than from invading fibroblasts alone.7PubMed. Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis
The Stiffness Feedback Loop
One of the most insidious features of fibrogenesis is that it feeds on itself. As collagen accumulates, the tissue stiffens. That increased stiffness is not just a passive consequence of scarring; it is an active signal that pushes fibroblasts to become more fibrotic. Researchers have identified a pair of mechanosensory proteins called YAP and TAZ that act as coordinators of this feedback loop. When fibroblasts sense a stiff environment, YAP and TAZ move into the cell nucleus and amplify the pro-fibrotic gene program, producing more collagen, which stiffens the tissue further.8PubMed Central. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
This mechanical signal intersects directly with the TGF-β pathway. In kidney tissue, for example, growing fibroblasts on a soft surface caused YAP and TAZ to stay out of the nucleus, which impaired TGF-β’s ability to activate its downstream gene program. On a stiff surface, YAP and TAZ entered the nucleus freely, and TGF-β signaling proceeded at full strength.9PubMed Central. YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis The implication is that once an organ passes a certain stiffness threshold, TGF-β and tissue mechanics gang up on the tissue, making reversal progressively harder.
How Fibrogenesis Differs by Organ
Although the core machinery of fibrogenesis is shared across the body, each organ has its own twist on the process. The cells that initiate scarring, the triggers that activate them, and the consequences of excess collagen vary significantly from one tissue to another.
Liver
The liver has a resident cell type called the hepatic stellate cell that, in healthy tissue, quietly stores vitamin A. When the liver is injured by alcohol, viral hepatitis, or metabolic disease, stellate cells activate and start producing large amounts of collagen.10PubMed Central. Hepatic stellate cells in physiology and pathology They also recruit other collagen-producing cells, including portal fibrocytes and bone marrow-derived myofibroblasts, amplifying the scarring response through chemical cross-talk with neighboring cells.11PubMed Central. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets The good news is that the liver has a remarkable capacity for fibrosis reversal if the underlying cause is removed, such as when antiviral drugs clear a hepatitis infection. Stellate cells can deactivate, and immune cells can clear existing scar tissue. This is one of the few organs where clinical reversal of established fibrosis has been convincingly demonstrated.
Heart
After a heart attack, two distinct forms of fibrosis occur. Replacement fibrosis fills the dead zone with scar tissue, which is essential because without it the heart wall could rupture. But the increased mechanical stress on the surviving heart muscle, combined with hormonal and local chemical signals, also triggers reactive fibrosis in areas far from the original damage. This reactive scarring stiffens the heart chambers, reduces their ability to fill and pump, and contributes to heart failure.12PubMed Central. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration The replacement scar is a lifesaver; the reactive fibrosis is the slow-burning problem.
Kidney
In the kidney, fibrogenesis takes the form of tubulointerstitial fibrosis, scarring in the tissue surrounding the kidney’s filtering tubules. Whether an injury leads to recovery or to progressive fibrosis appears to depend on how severe and how frequent the insult is. Mild, one-time injuries allow tubular epithelial cells to regenerate normally, but severe or repeated damage pushes those same cells into a maladaptive repair pattern that actively promotes scarring rather than healing.13Cell Death & Disease. Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury Despite decades of research into renal fibrogenesis, effective treatments to directly halt or reverse it in humans remain elusive.14Journal of the American Society of Nephrology. Mechanisms of Tubulointerstitial Fibrosis The kidney also stiffens as fibrosis advances, which engages the same YAP/TAZ feedback loop described earlier, making late-stage disease especially difficult to treat.
A complicating factor across all these organs is the loss of small blood vessels. Fibrotic tissue tends to choke off capillaries, a phenomenon called capillary rarefaction, which starves the remaining healthy cells of oxygen. The resulting low-oxygen environment activates hypoxia-inducible factor (HIF) signaling, which paradoxically promotes even more fibrosis.15PubMed Central. Hypoxia-inducible factor signaling in the development of tissue fibrosis It is another self-reinforcing loop layered on top of the mechanical one.
Immune Cells as Both Helpers and Harm-Doers
Macrophages, the immune cells that clean up damaged tissue after injury, have a complicated relationship with fibrogenesis. The amount of scar tissue that forms is directly related to the degree of inflammation, and a particular type of macrophage, commonly called M2, plays a dual role. M2 macrophages show up in large numbers during the fibrotic phase of healing and carry features associated with both promoting fibrosis and controlling it.16PubMed Central. Macrophages During the Fibrotic Process: M2 as Friend and Foe They help resolve inflammation, which is good, but they also secrete signals that encourage continued collagen production. This dual nature is one reason that broadly suppressing the immune response does not reliably prevent or treat fibrosis: you risk eliminating the macrophage functions that limit scarring while trying to shut down the ones that drive it.
The immune microenvironment matters in less obvious ways too. In radiation-induced fibrosis, the immune landscape of the irradiated area appears to play a key regulatory role in whether and how aggressively fibrosis develops.17PubMed. Radiation-induced fibrosis: Mechanisms and therapeutic strategies from an immune microenvironment perspective The composition of immune cells that persist in the tissue after the acute injury resolves shapes the chronic outcome.
Collagen Cross-Linking and Matrix Quality
Fibrogenesis is not only about how much collagen gets made; it is also about how that collagen is assembled. Enzymes called lysyl oxidases chemically cross-link collagen fibers, giving scar tissue its mechanical toughness. When lysyl oxidase activity was blocked experimentally in tendon cells, the resulting collagen fibrils were not just weaker but structurally abnormal, with irregular shapes and wildly varying diameters.18PubMed Central. Lysyl Oxidase Activity Is Required for Ordered Collagen Fibrillogenesis by Tendon Cells In normal repair, this cross-linking is tightly regulated. In pathological fibrosis, lysyl oxidase activity can become excessive, locking collagen into dense, rigid networks that resist degradation. Targeting these cross-linking enzymes is one therapeutic avenue under investigation, though early results have been mixed because the enzymes are also needed for normal tissue maintenance.
Diagnosing Fibrosis Without a Biopsy
Historically, the only way to confirm and stage fibrosis was to take a tissue sample with a needle biopsy. In the liver, this meant inserting a needle between the ribs, with associated pain and a small risk of bleeding. The push toward noninvasive alternatives has produced two broad categories of tools: blood-based biomarkers and imaging techniques. Serum biomarkers can now be used not only to detect fibrosis but also to monitor response to treatment and predict outcomes like the development of liver cancer.19PubMed Central. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions
On the imaging side, techniques that measure tissue stiffness have become particularly useful, since stiffness tracks closely with the degree of collagen deposition. Transient elastography (often sold under the brand name FibroScan), shear wave elastography, and magnetic resonance elastography each use different physical principles to estimate how stiff an organ has become.20PubMed Central. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future These have been most extensively validated in the liver, but similar approaches are being developed for the lungs, heart, and kidneys. The shift toward noninvasive monitoring matters for patients because it allows more frequent tracking of disease progression or treatment response without repeated biopsies.
Current Treatments and Experimental Approaches
For most fibrotic conditions, the first-line strategy is still to remove or treat the underlying cause: clear the virus, stop the alcohol, control blood sugar, adjust medication. If the injury stops early enough, some organs, especially the liver, can partially reverse existing fibrosis on their own.
The two drugs approved specifically for lung fibrosis, nintedanib and pirfenidone, work through multiple mechanisms. Both reduce collagen gene expression and collagen secretion from fibroblasts, and electron microscopy shows that treated cell cultures produce fewer and thinner collagen fibrils than untreated ones. Both drugs also directly slow the assembly of purified collagen molecules into fibrils in a test tube, a mechanism that was not initially anticipated when the drugs were developed.21American Journal of Respiratory Cell and Molecular Biology. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly They have also been shown to reduce fibrosis markers by inhibiting a signaling molecule called JAK2, which sits downstream of the TGF-β receptor.22PubMed Central. Pirfenidone and nintedanib attenuate pulmonary fibrosis in mice by inhibiting the expression of JAK2 These drugs slow disease progression in idiopathic pulmonary fibrosis but do not cure it or reverse established scarring, which is why the search for better therapies continues.
One of the more striking experimental directions is the use of engineered immune cells, known as CAR-T cells, to seek out and destroy the cells responsible for making scar tissue. In mouse models of chronic kidney disease, CAR-T cells targeting a surface protein called PDGFRβ reduced fibrosis in the kidney, heart muscle, and blood vessels without obvious toxic effects. The approach also showed promise in a human kidney organoid model of chronic kidney disease.23PubMed. Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease CAR-T therapy is already established in cancer treatment, so the infrastructure for producing and delivering these cells exists, though adapting it for a chronic condition with ongoing fibroblast activation poses distinct challenges.
Another avenue targets myofibroblast survival. In fibrotic lungs, myofibroblasts become resistant to apoptosis, the normal process of programmed cell death that should remove them once repair is complete. Research into compounds that restore this death program has identified phaseoloidin, a natural product that activates a cellular recycling process called autophagy in myofibroblasts, both breaking down a protein that blocks apoptosis and enhancing the turnover of excess extracellular matrix.24PubMed Central. Reversal of Myofibroblast Apoptosis Resistance and Collagen Deposition by Phaseoloidin-Induced Autophagy Attenuates Pulmonary Fibrosis Clearing myofibroblasts that have overstayed their welcome and degrading the matrix they left behind are the two essential requirements for fibrosis resolution.25PubMed Central. Mechanisms of Lung Fibrosis Resolution
Senescent Cells and the Aging Connection
Cellular senescence, where cells stop dividing but refuse to die, plays a growing role in fibrogenesis as people age. Senescent cells accumulate in tissues over time and secrete a cocktail of inflammatory molecules, growth factors, and matrix-remodeling enzymes collectively known as the senescence-associated secretory phenotype. While senescence can help with normal wound repair in limited doses, in excess it drives the kind of chronic, low-grade inflammation and metabolic dysfunction that tips healing toward scarring. Idiopathic pulmonary fibrosis is one of the clearest examples: it predominantly affects older adults, and preclinical studies using “senotherapeutics,” drugs that clear senescent cells or dampen their secretions, have shown improvements in age-related fibrotic disease in animal models.26PubMed Central. Cellular Senescence in Idiopathic Pulmonary Fibrosis This connection between aging and fibrosis helps explain why conditions like heart failure, chronic kidney disease, and pulmonary fibrosis become dramatically more common with advancing age.
Epigenetic Memory and Why Re-Injury Is Worse
A recent discovery adds a troubling dimension to the picture. Lung tissue that has previously experienced fibrosis and apparently resolved it may retain a molecular memory of that first injury. Researchers used genetic labeling to track lung connective-tissue cells through the full cycle of fibrosis, from initiation through progression and resolution, and found something surprising: although the cells showed remarkable ability to switch their gene programs on and off as fibrosis developed and then subsided, they responded more aggressively to a second injury. In other words, the fibrotic program was easier to reactivate after the tissue had been through it once. The transcription factor RUNX1 was identified as a critical driver of both the initial fibrotic activation and this epigenetic memory.27PubMed Central. RUNX1 is a mediator of fibrotic activation and epigenetic memory in lung fibroblasts
This has practical implications. It suggests that people who have recovered from a bout of organ fibrosis may be more vulnerable to it the next time that organ is injured, even if the first episode resolved fully. It also opens a potential therapeutic target: if the memory can be erased or blocked, the tissue might respond to a second insult as if it were the first time.
The Gut-Lung Axis
Research is also uncovering unexpected connections between gut bacteria and fibrogenesis in distant organs. In mouse models of pulmonary fibrosis induced by two different methods, a common metabolite, the amino acid L-tryptophan, was found to be significantly elevated in both lung tissue and blood. L-tryptophan levels correlated with the abundance of specific gut bacterial groups, suggesting that changes in the gut microbiome could be influencing the metabolic environment in the lungs.28npj Biofilms and Microbiomes. Roles of gut microbiome-associated metabolites in pulmonary fibrosis by integrated analysis This “gut-lung axis” is still in early stages of investigation, but it raises the possibility that the systemic metabolic environment shaped by the microbiome could either promote or restrain fibrosis in ways that have nothing to do with local tissue injury.
Lessons from Animals That Do Not Scar
Not all vertebrates default to scarring when they are injured. Salamanders, zebrafish, and certain other species can regenerate complex tissue with little or no fibrosis, and comparing their healing process with the mammalian version has generated a rich body of insight into what makes the difference.29PubMed Central. Finding Solutions for Fibrosis: Understanding the Innate Mechanisms Used by Super-Regenerator Vertebrates to Combat Scarring Even within a single animal, the outcome can vary by body region. Axolotl tail skin regenerates without scarring, but dorsal (back) skin heals with fibrotic scarring. The key differences identified include faster re-epithelialization, less collagen deposition, and a prolonged retention of an immature cell state in the tail skin, along with higher expression of a matrix protein called Tenascin-N and activation of downstream signaling pathways that appear to favor regeneration over fibrosis.30PubMed Central. Comparative analysis of dorsal and tail skin reveals region-dependent heterogeneity in axolotl skin regeneration
The finding that regenerative capacity can differ between body sites in the same animal suggests that the “decision” between scarring and regeneration is not purely a species-level trait but can be influenced by the local cellular environment and developmental history of the tissue. If the signals that tip the balance toward scarless repair can be identified and replicated, they could eventually inform treatments that nudge human tissue toward regeneration rather than fibrosis. That prospect remains distant, but the axolotl and its cousins continue to offer clues that no amount of studying mammalian wound healing alone would reveal.